Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression

Jiao Zou; Linlin Zhu; Xiaomei Jiang; Yang Wang; Yue Wang; Xiangwei Wang; Bin Chen

doi:10.18632/oncotarget.24109

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression

Jiao Zou _, Linlin Zhu, Xiaomei Jiang, Yang Wang, Yue Wang, Xiangwei Wang and Bin Chen

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:11268-11278. https://doi.org/10.18632/oncotarget.24109

Metrics: PDF 1893 views | HTML 4981 views | ?

Abstract

Jiao Zou1,*, Linlin Zhu1,*, Xiaomei Jiang1, Yang Wang1, Yue Wang1, Xiangwei Wang2 and Bin Chen1

1Department of Biochemistry and Molecular Biology, Third Military Medical University, Chongqing 400038, China

2Department of Urology, Shenzhen University General Hospital, Shenzhen 518060, Guangdong, China

*These authors contributed equally to this work

Correspondence to:

Bin Chen, email: [email protected]

Keywords: FEN1; curcumin; cisplatin resistance; breast cancer; ERK

Received: February 04, 2017 Accepted: December 03, 2017 Published: January 10, 2018

ABSTRACT

Flap endonuclease 1 (FEN1) overexpression promotes breast cancer. We investigated the role of FEN1 in cisplatin resistance and the chemosensitizing effects of curcumin in breast cancer cells. We demonstrated that FEN1 overexpression promotes cisplatin resistance in breast cancer cells, and that FEN1 knockdown enhances cisplatin sensitivity. Curcumin down-regulated FEN1 expression in a dose-dependent manner. A combination of cisplatin and curcumin enhanced breast cancer cell sensitivity to cisplatin by down-regulating FEN1 expression in vitro and in vivo. Increased ERK phosphorylation contributed to cisplatin resistance and cisplatin-induced FEN1 overexpression in breast cancer cells. Inhibiting ERK phosphorylation stimulated the chemosensitizing effect of curcumin to cisplatin by targeting FEN1. These data reveal that FEN1 overexpression promotes cisplatin resistance, and suggest FEN1 could be a potential therapeutic target to relieve cisplatin resistance in breast cancer. We also demonstrated that curcumin sensitizes breast cancer cells to cisplatin through FEN1 down-regulation.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24109

Publication Alerts

Research Papers:

Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression

Abstract